Person:
ERBAY, MÜGE

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

ERBAY

First Name

MÜGE

Name

Filters

2021 - 20223
Reset filters

Settings

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Publication
    Fatigue: A forgotten symptom of asthma
    (Wiley, 2021-03-29) Günaydın, Fatma Esra; Ediger, Dane; Erbay, Müge; GÜNAYDIN, FATMA ESRA; EDİGER, DANE; ERBAY, MÜGE; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı/İmmünolji ve Alerji Hastalıkları Bölümü; 0000-0002-9268-1071; 0000-0002-2954-4293; 0000-0003-3948-7007; HKV-2265-2023; HJA-1363-2022; AAE-9142-2019
    Objective Fatigue is a common symptom frequently reported in many disorders but little is known about the prevalence of fatigue in asthma. The objective of this study was to determine the prevalence of fatigue in asthmatic patients, the effect of fatigue on asthma quality of life and the relationship between fatigue and anxiety/depressionMaterials and methods This prospective cross-sectional study was conducted in Uludag University Faculty of Medicine, Department of Immunology and Allergic Diseases outpatient clinic from June 2019 to December 2019. Fatigue was assessed using the Checklist Individual Strength-Fatigue (CIS-Fatigue), psychological distress was assessed using the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI) and quality of life were assessed using the Asthma Quality of Life Questionnaire (AQLQ).Results In the present study, a total of 168 patients are included with an average age of 43.8 +/- 4.3 years. Nearly 64.8% of patients had controlled asthma and (35.2%) patients had uncontrolled asthma. Fatigue (CIS-Fatigue >= 27 points) was detected in 62.6% of patients and associated with asthma-related quality of life, asthma control, dyspnea, depression and anxiety (P < 0.05). However, the degree of lung function impairment and asthma severity were not associated with fatigue.Conclusions Fatigue as a symptom is common in asthmatic patients and correlates with asthma-related quality of life, asthma control, dyspnea, depression and anxiety. Future studies are needed to better understand the physical, psychological, behavioural and systemic factors that precipitate or perpetuate fatigue in asthma.
  • No Thumbnail Available
    Publication
    Fatigue: A forgotten symptom of asthma
    (Wiley, 2021-11-01) Gunaydin, Fatma Esra; Ediger, Dane; Erbay, Müge; GÜNAYDIN, FATMA ESRA; EDİGER, DANE; ERBAY, MÜGE; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı/İmmünoloji ve Alerji Bilim Dalı.; 0000-0002-9268-1071; 0000-0002-2954-4293; HKV-2265-2023; AAE-9142-2019; IKM-5924-2023
  • No Thumbnail Available
    Publication
    Efficacy of omalizumab treatment in patients with asthma-chronic obstructive pulmonary disease overlap (aco)
    (Bilimsel Tip Yayinevi, 2022-01-19) Ediger, Dane; EDİGER, DANE; Erbay, Müge; ERBAY, MÜGE; Şeker, Ümmühan; ŞEKER, ÜMMÜHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-2954-4293; AAE-9142-2019; HJA-1363-2022; JCN-9554-2023
    Objective: Although the precise definition of asthma-chronic obstructive pulmonary disease overlap (ACO) is still controversial, patients sharing common features of both diseases are frequently seen in clinical practice. Current literature suggests that patients with ACO have higher risk of morbidity and mortality than those with asthma or chronic obstructive pulmonary disease (COPD) alone. Omalizumab, a monoclonal anti-IgE monoclonal antibody, has proven to be effective in moderate-to-severe allergic asthma, but data on the efficacy of omalizumab in patients with ACO are limited. To determine the efficacy of omalizumab in patients with ACO.Materials and Methods: We assessed the effectiveness of omalizumab on 12 patients who met the criteria of ACO, using data from medical files of patients with severe allergic asthma who were treated with omalizumab between 2013 and 2018 at a University hospital.Results: Five (41.7%) patients responded well and seven (58.3%) patients responded partially to omalizumab treatment. Decreased number of hospitalizations and exacerbations (p = 0.016 and p = 0.003, respectively) and increased asthma control test results (ACT) (p=0.003) were observed after omalizumab treatment. No significant improvement in pulmonary function tests (FEV1%, FEV1(liter), FEV1/FVC) was found (p=0.444, p=0.208, p=0.510, respectively).Conclusion: Omalizumab was found to reduce asthma exacerbations and improve asthma control in a group of patients with ACO.